Trinity Biotech Plc

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Trinity Biotech reports robust Q1 results, eyes $75M revenue milestone

Trinity Biotech's Q1 2024 performance reflects strong revenue growth, margin improvement, and cost optimization efforts. Despite challenges in compliance and operational optimization, the company is poised for growth with a clear focus on key priorities and revenue targets.

Trinity Biotech reports revenue growth and operational progress in Q2

Trinity Biotech's Q2 2024 performance showed revenue growth and operational improvements, with a focus on strategic transformation and market expansion.
While facing financial challenges and cost pressures, the company is leveraging strengths in point-of-care sales and technology advancement for future success.
Opportunities for growth and profitability exist through achieving revenue targets, optimizing operations, and driving innovation in key product lines.
Overall, Trinity Biotech's progress in Q2 2024 sets a foundation for future growth and value creation, underpinned by a clear strategic roadmap.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN, Ireland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2020.

Trinity Biotech Announces Results for Q3, 2020

Conference Call Scheduled for November 17, 2020 at 11:00 am EASTERN Conference Call Scheduled for November 17, 2020 at 11:00 am EASTERN

Trinity Biotech plc to Announce Third Quarter 2020 Financial Results

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q2 2020 Results - Earnings Call Transcript

DUBLIN, Ireland, Aug.  25, 2020  (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2020.

Trinity Biotech Announces Results for Q2, 2020

DUBLIN, Ireland, Aug.  20, 2020  (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets announced that it has filed its submission for an Emergency Use Authorization (EUA) for its Covid-19 IgG ELISA antibody test with the FDA. This test will determine which individuals within the population have been exposed to the SARS-CoV-2 virus. The transfer of production to our facility in Jamestown, New York is complete, our manufacturing capability is very significant and the instrumentation platforms that perform ELISA testing are available in virtually every testing laboratory in the world.

Trinity Biotech announces EUA submission for Covid-19 ELISA Antibody test

Conference Call Scheduled for August 25, 2020  at 11:00am EASTERN Conference Call Scheduled for August 25, 2020  at 11:00am EASTERN

Trinity Biotech plc to Announce Second Quarter 2020 Financial Results

Trinity Biotech (NASDAQ: TRIB) shares are trading lower on Monday after the company's subsidiary Primus Corp announced it received an FDA warning letter following an inspection of Kansas City Manufacturing facility that took place in January.

Why Trinity Biotech's Stock Is Trading Lower Today

DUBLIN, Ireland, Aug.  17, 2020  (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced that its subsidiary Primus Corporation has received a warning letter from the U.S. Food and Drug Administration (FDA) following an inspection of its Kansas City, Missouri manufacturing facility that took place in January 2020. The issues identified in this letter primarily relate to the company’s Ultra2 product range.

Trinity Biotech subsidiary, Primus Corporation Receives FDA Warning Letter

Trinity Biotech's (TRIB) CEO Ronan O'Caoimh on Q1 2020 Results - Earnings Call Transcript

DUBLIN, Ireland, May  27, 2020  (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2020.

Trinity Biotech Announces Results for Q1, 2020

Trinity Biotech plc's (TRIB) CEO Ronan O'Caoimh on Q4 2019 Results - Earnings Call Transcript

Trinity Biotech PLC (NASDAQ: TRIB) released its fiscal fourth-quarter financial results on Tuesday morning, but that wasn’t what propelled the stock afterward.

What Trinity Bio Brings to the Fight Against COVID-19

Benitec Biopharma Limited Sponsored ADR

Grupo Supervielle

Penny stocks can be dangerous, particularly in this economic environment – so quick thinking and stop losses will be your best friends.

Penny Stocks to Buy Using Technical Analysis for March 2020

DUBLIN, Ireland, Oct.  16, 2019  (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2019.

Trinity Biotech Announces Results for Q3, 2019

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q2 2019 Results - Earnings Call Transcript

DUBLIN, Ireland, Aug.  20, 2019  (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2019.

Trinity Biotech Announces Results for Q2, 2019

For more than five years, shares of Trinity Biotech have woefully under-performed peers and the market.

Trinity Biotech's Next Act Could Surprise Investors

Trinity Biotech PLC (TRIB) CEO Ronan O'Caoimh on Q1 2019 Results - Earnings Call Transcript

News for Trinity Biotech Plc Stock (TRIB)